1 / 15

Training Initiative in Thrombocytopenia, Anaemia and Neutropenia Introduction

Training Initiative in Thrombocytopenia, Anaemia and Neutropenia Introduction. Training Initiative in Thrombocytopenia, Anaemia and Neutropenia A collaborative project of the European Oncology Nursing Society and European Society for Blood and Marrow Transplantation.

rpelletier
Download Presentation

Training Initiative in Thrombocytopenia, Anaemia and Neutropenia Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Training Initiative in Thrombocytopenia, Anaemia and NeutropeniaIntroduction

  2. Training Initiative in Thrombocytopenia, Anaemia and Neutropenia A collaborative project of the European Oncology Nursing Society and European Society for Blood and Marrow Transplantation

  3. History of TITAN 2018 update Training initiative developed by EONS 2008 Previous TITAN courses have been translated into 13 languages Nurses from 25 countries have participated 2008-2016

  4. TITAN provides an opportunity Improve the prevention, detection and management of haematological toxicities in patients with cancer Give nurses greater knowledge to assess, manage and educate patients with haematological toxicities High quality patient care and improved patient outcomes

  5. Learning objectives • Describe different types of blood cells, including their functions and normal development and lifespan • Define normal and abnormal blood values and their consequences • Define haematological toxicities • Consider aspects for effective patient education of haematological toxicities

  6. TITAN – the key elements

  7. Interactive course • Course structure • presentations of core subject areas • multiple choice questions for each section • supporting activities and case studies • Course designed to be interactive • freedom to ask questions throughout the day • ‘networking’ opportunities during intervals • Course evaluation is important • please complete and return your forms throughout the day as we go through the different parts of the course

  8. TITAN – an essential topic Negative impact on patient outcomes Cancer treatments  Dose intensity Myelosuppression Haematological toxicities Acute life-threatening consequences

  9. Why do these toxicities matter?1. Impact on dose intensity total dose delivered time to complete therapy Dose intensity = Reducing the dose delivered, or the time to complete therapy, impacts on the relative dose intensity (RDI) Low RDI increases risk of poorer treatment outcomes

  10. Why do these toxicities matter?2. Impact of age Age-related pharmacokinetic changes increase cancer-treatment toxicities Age-related decline in pluripotent haematopoietic stem cell reserve delays recovery of blood counts Elderly patients may be under-treated because of concerns regarding toxicities Elderly patients would benefit from proactive haematopoietic support to optimise treatment

  11. Potential life-threatening consequences Neutropenia Anaemia Thrombocytopenia Risk of infection and Febrile Neutropenia Impact on Quality of life Risk of bleeding and haemorrhage

  12. Essential role of the nurse • Assessing and identifying high risk patients • Contributing to pro-active management strategies • Making patients and their families aware of the implications and impact of haematological toxicities • Educating patients and their families about prevention and early detection strategies • symptoms often appear in the home environment

  13. Evidence base Risk assessment models: identify and validate risk factors Impact of myelosuppression on vulnerability to infection Underpins clinical guidelines: establish trigger values and targets for interventions Clinical practice Use assessment to select patients most vulnerable to myelosuppression Educate patients about haematological toxicities Monitor patient blood counts and symptoms over time, know when to intervene Importance of evidence-based clinical practice

  14. TITAN – an essential topic Negative impact on patient outcomes Cancer treatments  Dose intensity Myelosuppression Haematological toxicities Acute life-threatening consequences Neutropenia Anaemia Thrombocytopenia

  15. Training Initiative in Thrombocytopenia, Anaemia and Neutropenia

More Related